Double-blind randomized study on the myeloprotective effect of melatonin in combination with carboplatin and etoposide in advanced lung cancer

British Journal of Cancer

Volumn 80, Issue 7, 1999, Pages 1058-1061

  Ghielmini, M ^a   Pagani, O ^a   De Jong, J ^a   Pampallona, S ^c   Conti, A ^b   Maestroni, G ^b   Sessa, C ^a   Cavalli, F ^a  

^a OSPEDALE SAN GIOVANNI   (Switzerland)

^b INSTITUTE OF PATHOLOGY   (Switzerland)

^c ForMed   (Switzerland)

Author keywords

Chemotherapy; Hormones; Melatonin; Myelotoxicity

Indexed keywords

CARBOPLATIN; ETOPOSIDE; HEMOGLOBIN; MELATONIN;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG CANCER; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW DISEASES; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CROSS-OVER STUDIES; CYTOPROTECTION; DOUBLE-BLIND METHOD; ETOPOSIDE; FEMALE; HEMATOLOGIC TESTS; HUMANS; LEUKOPOIESIS; LUNG NEOPLASMS; MALE; MELATONIN; MIDDLE AGED; PROTECTIVE AGENTS; TREATMENT OUTCOME;

EID: 0032903822     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690463     Document Type: Article

References (21)

1. Aldeghi R, Lissoni P, Barni S, Ardizzola A, Tancini G, Piperno A, Pozzi M, Ricci G, Conti A and Maestroni GJM (1994) Low-dose interleukin-2 subcutaneous immunotherapy in association with the pineal hormone melatonin as a first-line therapy in locally advanced or metastatic hepatocellular carcinoma. Eur J Cancer 30A: 167-170
2. Aldhous M, Franey C, Wright J and Arendt J (1985) Plasma concentrations of melatonin in man following oral absorption of different preparations. Br J Clin Pharmacol 19: 517-521
3. Arendt J (1996) Melatonin. Br Med J 312: 1242-1243
4. Brzezinski A (1997) Melatonin in humans. N Engl J Med 336: 186-195
5. Canellos GP (1994) High-dose therapy: here to stay or just visiting? J Clin Oncol 12: 5-6
6. Capizzi RL, Scheffler BJ and Schein PS (1993) Amifostine-mediated protection of normal bone marrow from cytotoxic chemotherapy. Cancer 72: 3495-3501
7. Crinò L, Clerici M, Figoli F, Carlini P, Ceci G, Cortesi E, Carpi A, Santini A, Di Costanzo F, Boni C, Meacci M, Corgna E, Darwish S, Scarcella L, Santucci A, Ballatori E and Tonato M (1995) Chemotherapy of advanced non-smalll-cell lung cancer: A comparison of three active regimens. A randomized trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.). Ann Oncol 6: 347-353
8. Genevay MC, Mormont C, Thomas F and Berthier R (1996) The synthetic tetrapeptide AcSDKP protects cells that reconstitute long-term bone marrow stromal cultures from the effects of mafosfamide (Asta Z 7654). Exp Hematol 24: 77-81
9. Gurney H, Dodwell D, Thatcher N and Tattersall MHN (1993) Escalating drug delivery in cancer chemotherapy: A review of concepts and practice part 1. Ann Oncol 4: 23-34
10. Ihde DC (1992) Chemotherapy of lung cancer. N Engl J Med 327: 1434-1441
11. Jelinek J, Fairbairn LJ, Dexter TM, Rafferty JA, Stocking C, Ostertag W and Margison GP (1996) Long-term protection of hematopoiesis against the cytotoxic effects of multiple doses of nitrosourea by retrovirus-mediated expression of human 06-alkylguanine-DNA-alkyltransferase. Blood 87: 1957-1961
12. Lissoni P, Barni S, Crispino S, Tancini G and Fraschini F (1989) Endocrine and immune effects of melatonin therapy in metastatic cancer patients. Eur J Cancer Clin Oncol 25: 789-795
13. Lissoni P, Tisi F, Barni S, Ardizzoia A, Rovelli F, Rescaldani R, Ballahio D, Benenti C, Angeli M, Tancini G, Conti A and Maestroni GJM (1992) Biological and clinical results of a neuroimmunotherapy with inteleukin-2 and the pineal hormone melatonin as a first line treatment in advanced non-small cell lung cancer. Br J Cancer 66: 155-158
14. Lissoni P, Barni S, Taricini G, Ardizzoia A, Ricci G, Aldeghi R, Brivio F, Tisi E, Rovelli F, Rescaldani R, Quadro G and Maestroni G (1994) A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma. Br J Cancer 69: 196-199
15. Machin D and Campbell MJ (1987) Statistical tables for the design of clinical trials. Blackwell Scientific Publications: Oxford.
16. Maestroni GJ, Conti A and Lissoni P (1994a) Colony-stimulating activity and hemopoietic rescue from cancer chemotherapy compounds are induced by melatonin via endogenous interleukin 4. Cancer Res 54: 4740-4743
17. Maestroni GJ, Covacci V and Conti A (1994b) Hematopoietic rescue via T-cell-dependent, endogenous granulocyte-macrophage colony-stimulating factor induced by the pineal neurohormone melatonin in tumour-bearing mice. Cancer Res 54: 2429-2432
18. Maestroni JM, Hertens E, Galli P, Conti A and Pedrinis E (1996) Melatonin-induced T-helper cell hematopoietic cytokines resembling both interleukin-4 and dynorphin. J Pineal Res 21: 131-139
19. Neri B, Fiorelli C, Moroni F, Nicita G, Paoletti MC, Ponchietti R, Raugei A, Santoni G, Trippitelli A and Grechi G (1994) Modulation of human lymphoblastoid interferon activity by melatonin in metastatic renal cell carcinoma. Cancer 73: 3015-3019
20. Stata Corp (1997) Stata Statistical Software. Stata corporation: (Abstract)
21. Waldhauser F, Waldhauser M, Lieberman HR, Deng M-H, Linch D and Wurtman RJ (1984) Bioavailability of melatonin in humans. Neuroendocrinology 39: 307-313